To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

January 31, 2024 updated by: Marinus Pharmaceuticals

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus

This is a multicenter, double-blind, randomized, placebo-controlled study that will evaluate the efficacy, safety, and tolerability of intravenous (IV) ganaxolone versus placebo co-administered with IV antiepileptic drug (AED) according to standard of care for the treatment of RSE. Approximately 70 participants will be randomized in a 1:1 ratio to receive ganaxolone IV solution or placebo IV solution along with standard of care (SOC) IV AED.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

70

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Austria
      • Linz, Austria, 4020
        • Kepler University Hospital
        • Contact:
          • Raimund Helbok
      • Salzburg, Austria, 5020
        • Paracelsus Medical University Salzburg, Christian Doppler University Hospital, Department of Neurology
        • Contact:
      • Vienna, Austria, A-1090
        • Medical University Vienna
        • Contact:
          • Ekaterina Pataraia
  • Belgium
      • Bruxelles, Belgium, 1070
      • Edegem, Belgium, 2650 Edegem
        • UZA University Hospital Antwerpen
        • Contact:
          • Sarah Weckhuysen
      • Leuven, Belgium, 3000
  • Croatia
      • Zagreb, Croatia, 10000
      • Zagreb, Croatia, 10040
        • Dubrava University Hospital
        • Contact:
  • Czechia
      • Brno, Czechia, 60200
        • Mazaryk University, Brno,The First Department of Neurology
        • Contact:
      • Ostrava, Czechia, 70852
      • Prague, Czechia, 150 06
  • Denmark
  • Finland
  • France
  • Germany
      • Erlangen, Germany, 91054
        • Universitätsklinikum Erlangen
        • Contact:
          • Hajo Hamer
      • Marburg, Germany, 35043
      • Osnabrück, Germany, 49076
      • Ulm, Germany, 89081
        • Universität- und Rehabilitationskliniken Ulm, RKU
        • Contact:
          • Jan Wagner
  • Hungary
      • Budapest, Hungary, 1145
  • Israel
  • Italy
      • Milan, Italy, 00-168
        • Universita Cattolica del Sacro Cuore
        • Contact:
          • Domenica Battaglia
      • Modena, Italy, 41100
      • Verona, Italy, 37126
        • Azienda Ospedaliera Universitaria Integrata Di Verona
        • Contact:
          • Tiziano Zanoni
  • Lithuania
      • Vilnius, Lithuania, 08661
  • Spain
  • Switzerland
      • Lausanne, Switzerland, 1011
  • United Kingdom
      • Oxford, United Kingdom, OX3 9DU

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Participant, participant's parent, guardian, or LAR must provide signed informed consent/assent, and once capable (per institution guidelines), there must be documentation of consent/assent by the participant demonstrating they are willing and aware of the investigational nature of the study and related procedures. Where allowed by law, where the participant lacks the capacity to make informed decisions regarding his/her medical treatment options, the treating clinician may follow their deferred consenting practices. The clinician will make the final decision based on the best interests of the participant.
  2. Male or females 18 years of age and older at the time of the first dose of IP.

  3. SE warranting imminent progression of treatment meeting the following criteria:

    a) A diagnosis of SE, warranting imminent progression of treatment for seizure control, with or without prominent motor features based on clinical and EEG findings:

    i. Diagnosis is established by:

    • For SE with prominent motor features: Clinical and EEG seizure activity indicative of convulsive, myoclonic, or focal motor SE.
    • For SE without prominent motor features (nonconvulsive SE): Appropriate clinical features and an EEG indicative of non-convulsive status epilepticus (NCSE).

    ii. For any type of SE:

    • At least 6 minutes of cumulative seizure activity over a 30-minute period within the hour before IP initiation, AND Seizure activity during the 30 minutes immediately prior to IP initiation.

  4. Participants must have received a benzodiazepine and at least 1 of the following IV AEDs for treatment of the current episode of SE administered at an adequate dose and for a sufficient duration, in the judgement of the investigator, to demonstrate efficacy. The benzodiazepine and at least 1 of the IV AEDs must have been administered at a dose that would be expected to be effective for the termination of the current episode of SE.

    • IV Fosphenytoin/phenytoin,
    • IV Valproic acid,
    • IV Levetiracetam,
    • IV Lacosamide,
    • IV Brivaracetam, or
    • IV Phenobarbital.
  5. Body mass index (BMI) < 40 or, if BMI is not able to be calculated at screening, participant is assessed by investigator as not morbidly obese.

Exclusion Criteria:

  1. Life expectancy of less than 24 hours.
  2. Anoxic brain injury or an uncorrected, rapidly reversable metabolic condition as the primary cause of SE (eg, hypoglycemia < 50 milligrams per deciliter [mg/dL] or hyperglycemia > 400 mg/dL).
  3. Participants who have received high-dose IV anesthetics (eg, midazolam, propofol, thiopental, or pentobarbital) during the current episode of SE for more than 18 hours, or who continue to have clinical or electrographic evidence of persistent seizures while receiving high-dose IV anesthetics.
  4. Clinical condition or advance directive that would NOT permit admission to the ICU or use of IV anesthesia.
  5. Participants known or suspected to be pregnant
  6. Participants with known allergy or sensitivity to progesterone or allopregnanolone medications/supplements
  7. Receiving a concomitant IV product containing Captisol.
  8. Known or suspected hepatic insufficiency or hepatic failure leading to impaired synthetic liver function.
  9. Known or suspected stage 3B (moderate to severe; estimated glomerular filtration rate [eGFR] 44-30 milliliters per minute per 1.73-meter square [mL/min/1.73m^2]), stage 4 (severe; eGFR 29-15 mL/min/1.73m^2), or stage 5 (kidney failure; eGFR < 15 mL/min/1.73m^2 or dialysis) kidney disease.
  10. Use of an investigational product for which less than 30 days or 5 half-lives have elapsed from the final product administration. Participation in a non-interventional clinical study does not exclude eligibility.
  11. Known or suspected history or evidence of a medical condition that, in the investigator's judgment, would expose a participant to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ganaxolone IV solution + SOC IV AED
Drug: Ganaxolone
Ganaxolone will be administered as IV solution.
Drug: Standard of care
A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
Experimental: Placebo IV solution + SOC IV AED
Drug: Standard of care
A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
Drug: Placebo
Placebo will be administered as IV solution.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of participants who will report cessation of SE within 30 minutes of investigational product (IP) initiation of at least 30 minutes duration
Time Frame: Up to 30 minutes
Status epilepticus cessation will be determined by the investigator based on clinical and electroencephalography (EEG) features
Up to 30 minutes
Percentage of participants who will report no escalation of treatment for persistent or recurrent SE within 36 hours of IP initiation
Time Frame: Up to 36 hours
Up to 36 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of participants who will report cessation of SE within 30 minutes of IP initiation of at least 30 minutes duration
Time Frame: Up to 30 minutes
Up to 30 minutes
Percentage of participants who will report no escalation of treatment for persistent or recurrent SE within 72 hours of IP initiation
Time Frame: Up to 72 hours
Up to 72 hours
Time to SE cessation
Time Frame: Up to 72 hours
Up to 72 hours
Percentage of participants having cessation of SE within 30 minutes of IP initiation of at least 30 minutes duration without escalation of treatment
Time Frame: Up to 30 minutes
Up to 30 minutes
Percentage of participants reporting no escalation of treatment for persistent or recurrent SE within 36 hours of IP initiation
Time Frame: Up to 36 hours
Up to 36 hours
Percentage of participants reporting no escalation of treatment for persistent or recurrent SE within 72 hours of IP initiation
Time Frame: Up to 72 hours
Up to 72 hours
Change from Baseline in Modified Rankin Scale (mRS) at the time of hospital discharge
Time Frame: Baseline and Up to Day 31
The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death where 0 - No symptoms; 1=No significant disability. Able to carry out all usual activities, despite some symptoms; 2=Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3=Moderate disability. Requires some help, but able to walk unassisted; 4=Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5=Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6=Dead. Higher scores will indicate high degree of disability.
Baseline and Up to Day 31
Change from Baseline in level of responsiveness as assessed by the Full Outline of UnResponsiveness (FOUR) Score scale
Time Frame: Baseline and at 24, 36 and 72 hours
The FOUR Score is a 17-point scale (with potential scores ranging from 0 - 16). Decreasing FOUR Score is associated with worsening level of consciousness. The FOUR coma scale includes 4 parameters with a minimum score of 0 and a maximum score of "4" for each of them: eye reactions (eye opening and tracking), motor responses (pain response and simple commands), stem reflexes (pupillary, corneal and cough) and respiratory patterns (respiratory rhythm and respiratory attempts in patients on a ventilator). The points are summed up, their sum is estimated. The interpretation of results will be as 15 to 16 score: clear consciousness; Less than 15: Impairment of consciousness; from 4 to 8: Coma and 0-4: Death. Lower the score, the greater the coma gravity.
Baseline and at 24, 36 and 72 hours
Change from Baseline in level of sedation/ agitation as assessed by Richmond Agitation and Sedation Scale (RASS)
Time Frame: Baseline and at 24, 36 and 72 hours
The RASS is a medical scale used to measure the agitation or sedation level. It is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm. higher scores indicate more agitation.
Baseline and at 24, 36 and 72 hours
Percentage of participants with mRS > 3 at the time of hospital discharge
Time Frame: Up to 122 hours
The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death where 0 - No symptoms; 1=No significant disability. Able to carry out all usual activities, despite some symptoms. 2=Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3=Moderate disability. Requires some help, but able to walk unassisted. 4=Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5=Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6=Dead. Higher scores will indicate high degree of disability.
Up to 122 hours
Change from Baseline in Clinical Global Impression-Improvement (CGI-I) following IP initiation and at hospital discharge
Time Frame: Baseline and at 24, 36, and 72 hours
The CGI-I is a 7-point Likert scale that the parent(s)/caregiver(s)/legally authorized representative (LAR)(s) and clinician uses to rate the change in overall seizure control, behavior, safety, and tolerability after initiation of the IP relative to Baseline (prior to treatment with the IP). It was rated as: 1- "very much improved", 2- "much improved', 3- "minimally improved", 4- "no change", 5- "minimally worse", 6- "much worse", and 7- "very much worse". Higher scores indicated worse condition.
Baseline and at 24, 36, and 72 hours
Number of hours on positive pressure ventilation attributable to the episode of SE or its treatment
Time Frame: Up to 4 Weeks
Healthcare Utilization Questionnaires include the Hospitalization Questionnaire and the Positive Pressure Ventilation (PPV) and Intubation Questionnaire. The Hospitalization Questionnaire should be collected at hospital discharge or at final study visit/contact. The need for non-invasive or invasive ventilatory support within 24 hours prior to IP initiation and following IP initiation and within 48 hours following IP discontinuation should be collected as close as possible to the event.
Up to 4 Weeks
Number of hours on positive pressure ventilation
Time Frame: Up to 4 Weeks
Up to 4 Weeks
Length of stay (days) in intensive care unit (ICU)
Time Frame: Up to 4 Weeks
Up to 4 Weeks
Length of stay (days) in hospital
Time Frame: Up to 4 Weeks
Up to 4 Weeks
Percentage of participants requiring artificial ventilation after initiation of IP
Time Frame: Up to 122 hours
Up to 122 hours
Percentage of participants not requiring IV anesthesia for SE treatment within 36 hours of IP initiation
Time Frame: Up to 36 hours
Up to 36 hours
Percentage of participants not requiring IV anesthesia for SE treatment within 72 hours of IP initiation
Time Frame: Up to 72 hours
Up to 72 hours
Percentage of participants not requiring IV anesthesia for SE treatment through the final study follow-up visit/contact
Time Frame: Up to 4 Weeks
Up to 4 Weeks
Percentage of participants who do not develop super refractory status epilepticus (SRSE) through the final study follow-up visit/contact
Time Frame: Up to 4 Weeks
Up to 4 Weeks
Change from Baseline in Euro Quality of Life (five-level EuroQoL five-dimensional [EQ-5D-5L]) score
Time Frame: Baseline and Up to 4 Weeks
The EQ-5D-5L is the EuroQoL 5D-5L, a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the participant's health state. A positive score means quality of life improvement, a negative score, a worsening of quality of life. Higher scores indicate more problems.
Baseline and Up to 4 Weeks
Number of AEDs at discharge
Time Frame: Up to 122 hours
Up to 122 hours
Percentage of participants requiring supplemental oxygen after initiation of IP
Time Frame: Up to 4 Weeks
Up to 4 Weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Marinus Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2024

Primary Completion (Estimated)

November 1, 2025

Study Completion (Estimated)

November 1, 2025

Study Registration Dates

First Submitted

April 3, 2023

First Submitted That Met QC Criteria

April 3, 2023

First Posted (Actual)

April 18, 2023

Study Record Updates

Last Update Posted (Actual)

February 1, 2024

Last Update Submitted That Met QC Criteria

January 31, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1042-SE-3004

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Refractory Status Epilepticus

Clinical Trials on Ganaxolone

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe